You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • OP0222 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 104 weeks results from a phase 3 trial, future 2

Article info

Article menu

Download PDFPDF

Oral Presentations
PsA: the options grow!
OP0222 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 104 weeks results from a phase 3 trial, future 2
Free

Authors

Citation

McInnes I, Mease P, Ritchlin C, et al
OP0222 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 104 weeks results from a phase 3 trial, future 2
Annals of the Rheumatic Diseases 2017;76:145.

Publication history

  • First published June 15, 2017.
Online issue publication 
January 09, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions